Trial Profile

A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jun 2026 According to an Abivax media release, topline results of Phase 2b induction trial for Crohn's disease expected in mid-year 2027
22 May 2026 According to an Abivax media release, the 12-week induction trial results are anticipated in Q4 2026.
08 Jan 2026 According to an Abivax media release, the 12-week induction trial results are anticipated in late 2026 and will help inform the design of subsequent registrational studies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com